Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial (original) (raw)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

Cardiovascular Diabetology, 2012

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

New England Journal of Medicine, 2013

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Robert Frederich

Diabetes Care, 2014

View PDFchevron_right

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

Robert Frederich

Cardiovascular Diabetology, 2014

View PDFchevron_right

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

Robert Frederich

Diabetology and Metabolic Syndrome

View PDFchevron_right

Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study

Bruce Fireman

Diabetes Care, 2017

View PDFchevron_right

Sitagliptin Use in Patients With Diabetes and Heart Failure

Dean Eurich

JACC: Heart Failure, 2014

View PDFchevron_right

The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session

Pablo Aschner

Diabetology & Metabolic Syndrome, 2010

View PDFchevron_right

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Kausik Ray

Diabetes care, 2017

View PDFchevron_right

Risk Assessment for Heart Failure in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase 4 Inhibitor Using a Large Claims Dataset

kenji momo

Biological and Pharmaceutical Bulletin

View PDFchevron_right

Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS

Guntram Schernthaner

Diabetes Care, 2016

View PDFchevron_right

Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus

Jasmine Gonzalvo

Clinical Therapeutics, 2011

View PDFchevron_right

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

German Malaga

BMJ, 2016

View PDFchevron_right

Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure

Rafay Ali Syed

PubMed, 2016

View PDFchevron_right

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Ivan Rychlík

Diabetes, Obesity and Metabolism, 2011

View PDFchevron_right

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial

I. Raz

Diabetes/Metabolism Research and Reviews, 2013

View PDFchevron_right

Does dipeptidyl peptidase IV inhibitor increase the risk of heart failure? A cardiologist’s paradox

tejas patel

Cardiovascular Endocrinology, 2014

View PDFchevron_right

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

jay shubrook

Clinical medicine insights. Endocrinology and diabetes, 2011

View PDFchevron_right

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Elizabeth Paz-Pacheco

Diabetes Obesity & Metabolism, 2009

View PDFchevron_right

Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database

Giuseppe M C Rosano

European heart journal, 2015

View PDFchevron_right

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs

Bruce Fireman

Annals of Internal Medicine, 2016

View PDFchevron_right

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study

Jimi Choi

Cardiovascular Diabetology

View PDFchevron_right

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

Dean Eurich

BMJ, 2007

View PDFchevron_right

A Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes

Danshi Li

Diabetes care, 2015

View PDFchevron_right

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

Melvin Munsaka

Diabetes, Obesity and Metabolism, 2013

View PDFchevron_right

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients

Alessandra D’Alessandro

Italian Journal of Medicine, 2016

View PDFchevron_right

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial (original) (raw)

Related papers